<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0609211013
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1994
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CO-RENITEC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ENALAPRIL MALEATE,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        66.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Organon Pharma (UK) Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Organon Pharma (UK) Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ORGANON
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor has prescribed CO-RENITEC to treat your hypertension (high blood pressure).</p><p>&nbsp;</p><p>The enalapril ingredient of CO-RENITEC is a medication that belongs to the group of drugs called angiotensin converting enzyme inhibitors (ACE inhibitors) and works by widening your blood vessels to make it easier for the heart to pump blood to all parts of your body. The hydrochlorothiazide ingredient of CO-RENITEC is a medication that belongs to the group of drugs called diuretics (water tablets) and works by making your kidneys pass more water and salt. Together, enalapril and hydrochlorothiazide help to reduce high blood pressure.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->RENITEC Do not take CO-RENITEC:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are allergic to enalapril maleate, hydrochlorothiazide , or any one of the other ingredients in this medicine. They are listed in section 6.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have previously been treated with a medication in the same group of drugs as this medicine (ACE inhibitors) and have had allergic reactions with swelling of the face, lips, tongue and/or &nbsp;throat with difficulty in swallowing or breathing. You should not take this medicine if you have had these types of reactions without a known cause, or if you have been diagnosed with hereditary or idiopathic angiooedema.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are allergic to any sulfonamide-derived drugs (ask your doctor if you are not sure what sulfonamide-derived drugs are)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are not passing urine</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have severe kidney problems</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are more than 3 months pregnant. (It is also better to avoid CO-RENITEC in early pregnancy</p><p>- see pregnancy section.)</p><p>&nbsp;</p><p>If you are not sure whether you should start taking this medicine, contact your doctor.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Tell your doctor about any medical problems you have or have had, and about any allergies.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if&nbsp; you have kidney problems, have had a recent kidney transplantation, are a dialysis patient, or are taking water tablets (diuretics).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have blood disorders or liver problems</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are on a salt restricted diet, or have suffered from excessive vomiting or diarrhoea recently</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if&nbsp; you&nbsp; have&nbsp; a&nbsp; heart&nbsp; condition&nbsp; called&nbsp; &lsquo;aortic&nbsp; stenosis&rsquo;,&nbsp; &lsquo;hypertrophic cardiomyopathy&rsquo; or &lsquo;outflow obstruction&rsquo;</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have collagen vascular disease, are taking immunosuppressant therapy (used for&nbsp; the&nbsp; treatment&nbsp; of&nbsp; autoimmune&nbsp; disorders&nbsp; such&nbsp; as&nbsp; rheumatoid&nbsp; arthritis&nbsp; or following transplant surgery)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are taking allopurinol, (used for the treatment of gout), or procainamide, (used to treat abnormal heart rhythms). If you develop an infection (symptoms may be high temperature or fever), you should let your doctor know immediately. Your doctor may take a blood sample from time to time to check your white blood cell count</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have a history of &lsquo;angioedema&rsquo; while taking other medicines. The signs may have been itching, nettle rash, wheezing or swelling of your hands, throat, mouth or eyelids</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have diabetes and are taking antidiabetic medicines, including insulin to control your diabetes (you should monitor your blood for low blood glucose levels, especially during the first month of treatment)</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are taking potassium supplements or potassium containing salt substitutes</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are taking lithium, used for the treatment of some psychiatric illnesses</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have been told by your doctor that you have an intolerance to some sugars.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you think you are (<u>or might become</u>) pregnant. This medicine is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->tell your doctor if you are taking either of the following medicines used to treat high blood pressure:</p><p><!--[if !supportLists]-->&sect; <!--[endif]-->an angiotensin II receptor blocker (ARB) (also known as sartans &ndash; for example valsartan, telmisartan, irbesartan etc), in particular if you have diabetes-related kidney problems.</p><p><!--[if !supportLists]-->&sect; <!--[endif]-->&nbsp;aliskiren</p><p><!--[if !supportLists]-->&sect;&nbsp;&nbsp;&nbsp; <!--[endif]-->tell your doctor if you suffer from low blood pressure (you may notice this as faintness or dizziness, especially when standing).</p><p>&nbsp;</p><p>&nbsp;</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g., potassium) in your blood at regular intervals.</p><p>See also information under the heading &lsquo;Do not take CO-RENITEC&rsquo;.</p><p>&nbsp;</p><p><strong>If you are about to have any of the following procedures, you should tell your doctor who is treating you that you are taking CO-RENITEC:</strong></p><p>&bull; &nbsp;any surgery or receive anaesthetics (even at the dentist)</p><p>&bull; &nbsp;a treatment called LDL apheresis, to remove cholesterol from your blood using a machine</p><p>&bull; &nbsp;desensitisation treatment, to reduce the effect of an allergy to bee or wasp stings.</p><p>&nbsp;</p><p>&nbsp;</p><p>Children and adolescents</p><p>Safety and effectiveness in children have not been established.</p><p>&nbsp;</p><p>Other medicines and CO-RENITEC</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your doctor may need to change your dose and/or to take other precautions.</p><p>In general, CO-RENITEC can be taken with other drugs. For prescribing the correct dose of</p><p>CO-RENITEC, it is especially important for your doctor to know whether you are taking any of the following medicines:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->An angiotensin II receptor blocker (ARB) or aliskiren (see also information under the headings &lsquo;Do not take CO-RENITEC&rsquo; and &lsquo;Warnings and precautions&rsquo;)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->potassium sparing water tablets (diuretics) such as spironolactone, eplerenone, triamterene or amiloride, potassium supplements, or potassium-containing salt substitutes. Co-Renitec may increase the levels of potassium in your blood leading to high potassium levels. This causes few signs and is usually seen by a test,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->water tablets (diuretics) such as thiazides, furosemide, bumetanide,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->other medicines that lower blood pressure, such as nitroglycerine, nitrates, and vasodilators, &nbsp;lithium, used for the treatment of some psychiatric illnesses. Co-Renitec should not be taken with this drug.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->barbiturates (sedatives used for sleeplessness or epilepsy),</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Tricyclic antidepressants such as amitriptyline , used for depression, &nbsp;antipsychotics such as phenothiazines, used for severe anxiety,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->pain killers such as morphine or anaesthetics, because your blood pressure may become too low,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->cholestyramine or colestipol (used to help control cholesterol levels),</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->medicines used for, stiffness and inflammation associated with painful conditions, particularly those affecting your muscles, bones and joints:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->including gold therapy which can lead to flushing of your face, feeling sick (nausea), vomiting and low blood pressure, when taken with Co-Renitec, and</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->non-steroidal anti-inflammatory drugs (NSAIDs), for example diflunisal or diclofenac. They may prevent your blood pressure from being well controlled and may increase the level of potassium in your blood</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->medicines such as ephedrine, used in some cough and cold remedies, or noradrenaline and adrenaline used for low blood pressure, shock, cardiac failure, asthma&nbsp; or&nbsp; allergies.&nbsp; If&nbsp; used&nbsp; with&nbsp; Co-Renitec these&nbsp; drugs&nbsp; may keep&nbsp; your&nbsp; blood pressure high,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ACTH (to test whether your adrenal glands are working properly),</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->corticosteroids&nbsp; (used&nbsp; to&nbsp; treat&nbsp; certain&nbsp; conditions&nbsp; such&nbsp; as&nbsp; rheumatism,&nbsp; arthritis, allergic conditions, asthma or certain blood disorders),</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->allopurinol (used to treat gout),</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ciclosporins (immunosuppressive agents used for autoimmune disorders),</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->medicines for the treatment of cancer,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->antacids (used for indigestion relief),</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->procainamide, amiodarone or sotalol (used to treat abnormal heart rhythms),</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->digitalis (used to treat heart rhythm problems),</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->carbenoxalone (used to treat stomach ulcers),</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->excessive use of laxatives,</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->antidiabetic medicines such as insulin. Co-Renitec may cause your blood sugar levels to drop even further if you take it with antidiabetics</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&bull;&nbsp; an mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) as coadministration could increase the risk for an allergic reaction called angioedema.</p><p>&nbsp;</p><p>CO-RENITEC with food and drink</p><p>CO-RENITEC can be taken with or without food. Most people take CO-RENITEC with a drink of water.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p><u>Pregnancy</u></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will normally advise you to stop taking</p><p>CO-RENITEC before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of CO-RENITEC. This medicine is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. This medicine is not recommended for mothers who are breast-feeding.</p><p>&nbsp;</p><p>Driving and using machines</p><p>&nbsp;</p><p>Certain side effects, such as dizziness and weariness, have been reported with this medicine which may affect some patients&rsquo; ability to drive or operate machinery (see Possible side effects).</p><p>&nbsp;</p><p>CO-RENITEC contains lactose</p><p>CO-RENITEC contains lactose, which is a type of sugar. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will decide on the appropriate dose, depending on your condition and whether you are taking other medicines.</p><p>&nbsp;</p><p>The usual dosage is one tablet, administered once daily. If necessary the dose may be increased to two tablets once daily. The maximum dose is two tablets once daily. Take this medicine with a drink of water.</p><p>&nbsp;</p><p>Patients with a history of kidney problems may require a lower dose of this medicine.</p><p>&nbsp;</p><p>Prior treatment with diuretics should be stopped 2-3 days before beginning treatment with this medicine.</p><p>&nbsp;</p><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. It is very important to continue taking this medicine for as long as your doctor prescribes it. Do not take more tablets than the prescribed dosage.</p><p>&nbsp;</p><p>If you take more CO-RENITEC than you should</p><p>In case of an overdose, contact your doctor immediately so that medical attention may be given promptly. The most likely symptoms would be a feeling of light-headedness or dizziness due to a sudden or excessive drop in blood pressure, excessive thirst, cough, confusion, fast breathing, anxiety, a decrease in the amount of urine passed, or fast or slow heart rate.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you forget to take CO-RENITEC</p><p>You should take this medicine as prescribed. Do not take a double dose to make up for a forgotten tablet. Just resume your usual schedule.</p><p>&nbsp;</p><p>If you stop taking CO-RENITEC</p><p>Do not stop taking your medicine unless your doctor tells you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following terms are used to describe how often side effects have been reported.</p><p>Very common (occurring in patients in at least 1 of 10 patients treated)</p><p>Common (occurring in at least 1 of 100 and less than 1 of 10 patients treated) Uncommon (occurring in at least 1 of 1000 and less than 1 of 100 patients treated) Rare (occurring in at least 1 of 10,000 and less than 1 of 1000 patients treated)</p><p>Very rare (occurring in less than 1 of 10,000 patients treated)</p><p>Not known (frequency cannot be estimated from the available data)</p><p>&nbsp;</p><p>Blood disorders:</p><p>Uncommon: anaemia (including aplastic and haemolytic)</p><p>Rare: changes in blood values such as a lower number of white and red blood cells, lower haemoglobin, lower number of blood platelets, swollen glands in neck, armpit or groin</p><p>&nbsp;</p><p>Immune system disorders</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden life-threatening allergic reaction</p><p>&nbsp;</p><p>Endocrine disorders:</p><p>Not known: overproduction of antidiuretic hormone, which causes fluid retention, resulting in weakness, tiredness or confusion</p><p>&nbsp;</p><p>Metabolism and nutrition disorders</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of potassium in the blood, increased levels of cholesterol or fat in the blood, high levels of uric acid in the blood</p><p>Uncommon: &nbsp;low blood sugar (hypoglycaemia), low levels of magnesium (hypomagnesaemia), disease with painful, swollen joints caused by uric acid crystals (gout)*, unusual amount of salt in the body (electrolyte imbalance, including hyponatraemia)</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in blood sugar</p><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high levels of calcium in the blood (hypercalcaemia)</p><p>&nbsp;</p><p>Nervous system and psychiatric disorders</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, depression, fainting (syncope), change in the sense of taste</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion, sleepiness, sleeplessness, nervousness, tingling without a cause (paresthesia), spinning sensation (vertigo), decreased sexual drive (libido)*</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; strange dreams, sleep problems, muscle weakness sometimes due to low potassium (paresis)</p><p>&nbsp;</p><p>Eye disorders</p><p>Very common: &nbsp;blurred vision</p><p>&nbsp;</p><p>Ear disorders</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears (tinnitus)</p><p>&nbsp;</p><p>Cardiac and vascular disorders</p><p>Very common: &nbsp;dizziness</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;low blood pressure (hypotension), light-headedness due to low blood pressure (including a drop in blood pressure when standing up quickly), angina or chest pain, change in heart rhythm, fast heartbeat</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing, fast or uneven heartbeats (palpitations), heart attack, stroke possibly due to excessively low blood pressure in high-risk patients (patients with blood flow disturbances of the heart and/or brain)</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; poor blood flow in the limbs (Raynaud&rsquo;s phenomenon)</p><p>&nbsp;</p><p>Respiratory, thoracic and mediastinal disorders</p><p>Very common: &nbsp;cough</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath (dyspnea)</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp; runny nose (rhinorrhea), sore throat and hoarseness, asthma associated tightness on the chest</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung infiltrates (local infection in lungs), respiratory distress including inflammation of the lungs (pneumonitis) and accumulation of fluid or other substances in the lungs (pulmonary oedema)(as seen on X-rays), inflammation of the nose (rhinitis), inflammation of the air sacs of the lungs (allergic alveolitis), pneumonia (eosinophilic pneumonia)</p><p>&nbsp;</p><p>Gastrointestinal disorders</p><p>Very common: &nbsp;nausea</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, abdominal pain</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slow movement of food through your intestine (ileus), inflammation of the pancreas (pancreatitis), vomiting, indigestion (dyspepsia), constipation, loss of appetite (anorexia), stomach pain and irritation, dry mouth, stomach (peptic) and intestinal ulcers (ulcus ventriculi), flatulence*</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth sores (stomatitis/aphthous ulceration), swollen tongue (glossitis) Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in your intestine (intestinal angioedema)</p><p>&nbsp;</p><p>Hepatobiliary disorders</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver dysfunctions, liver inflammation (hepatitis) with destruction of liver cells, jaundice (yellow discoloration of the eyes or skin), gall bladder problems (cholecystitis)</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash (exanthema), allergic reactions with swelling of the face, lips, tongue, and/or throat with difficulty swallowing or breathing</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating (diaphoresis), itching (pruritus), hives (urticaria), hair loss (alopecia), increased sensitivity of the skin to sun</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash that looks like targets (erythema multiforme), severe hypersensitivity reaction with high fever, Stevens-Johnson&rsquo;s syndrome and toxic epidermal necrolysis (severe skin conditions with reddening, scaling and blistering of the skin), severe skin rash with loss of skin and hair (exfoliative dermatitis), purple or red spots on the skin (purpura), cutaneous lupus erythematosus (an immune disease), red rash with peeling of the skin (erythroderma), small bumps filled with fluid on the skin (pemphigus)</p><p>&nbsp;</p><p>Not known: A symptom complex has been reported which may include some or all of the following: fever, inflammation of the blood vessels (serositis/vasculitis), muscle pain (myalgia/myositis), joint pain (arthralgia/arthritis). Rash or other skin manifestations may occur.</p><p>&nbsp;</p><p>&nbsp;</p><p>Musculoskeletal and connective tissue disorders</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle cramps** Uncommon: joint pain (arthralgia)*</p><p>&nbsp;</p><p>Renal and urinary disorders</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney problems (renal dysfunction), kidney failure, protein in the urine (proteinuria), sugar in the urine (glycosuria)</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced amount of urine (oliguria), kidney disease (interstitial nephritis)</p><p>&nbsp;</p><p>Reproductive system and breast disorders</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impotence</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast development in men (gynaecomastia)</p><p>&nbsp;</p><p>General disorders and administration site conditions</p><p>Very common: &nbsp;weakness (asthenia) Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain, fatigue</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling unwell (malaise), fever</p><p>&nbsp;</p><p>Laboratory tests</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high levels of potassium in the blood (hyperkalaemia), which may manifest as muscular cramp, increases in serum creatinine, diarrhea, nausea, dizziness and headache</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of urea in the blood, low level of sodium in the blood Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high levels of liver enzymes or bilirubin.</p><p>&nbsp;</p><p>Other side effects may also occur uncommonly or rarely, and some of them may be serious. Ask your doctor or pharmacist for more information about side effects. Both have a more complete list of side effects.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist promptly about these or any other unusual symptoms.</p><p>&nbsp;</p><p>Stop taking CO-RENITEC and contact your doctor immediately in any of the following cases:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you develop swelling of the face, lips, tongue and/or throat which may cause difficulty in breathing or swallowing</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you experience swelling of the hands, feet or ankles</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you develop hives.</p><p>&nbsp;</p><p>The initial dose may cause a greater fall in blood pressure than will occur following continued treatment. You may notice this as faintness or dizziness and it may help to lie down. If concerned, please consult your doctor.</p><p>&nbsp;</p><p>* Only seen with doses of hydrochlorothiazide 12.5 mg and 25 mg</p><p>** The frequency of muscle cramps as common pertains to doses of hydrochlorothiazide 12.5 mg and 25 mg, whereas, the frequency of the event is uncommon as it pertains to 6 mg doses of hydrochlorothiazide.</p><p>&nbsp;</p><p>Reporting side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via (the National Pharmacovigilance and Drug Safety Centre (NPC), SFDA). &nbsp;By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. Store below 30 &deg;C.</p><p>Store in the original package.</p><p>Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->What CO-RENITEC contains</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The active substances are enalapril maleate (20 mg) and hydrochlorothiazide (12.5 mg)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The other ingredients are sodium bicarbonate, lactose hydrous<strong>,</strong><strong> </strong>corn starch, pregelatinised starch, magnesium stearate (E572). Yellow ferric oxide (E172) has been used as a coloring agent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CO-RENITEC tablets are yellow, round, fluted shaped, with on one side the code ‘MSD 718’ and the other side scored.

Pack sizes: box with three blisters of 10 tablets and box with two blisters of 14 tablets. Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder:</strong></p><p>Merck Sharp &amp; Dohme B.V., Waarderweg 39,</p><p>2031 BN Haarlem, P.O. Box 581, 2003 PC Haarlem,</p><p>The Netherlands</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Merck Sharp &amp; Dohme Ltd. Shotton Lane,</p><p>Cramlington, Northumberland NE23 3JU</p><p>UK.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This package leaflet was last revised in July 2016.Version No. (02)
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>لقد وصف لك طبيبك كو- رينيتك لعلاج ارتفاع ضغط الدملديك.</p><p>اينالبريل ، أحد مكونات &nbsp;كو- رينيتك ، هو دواء ينتمي إلى مجموعة من الأدوية تسمى مثبطات الإنزيم المــُحوّل للأنجيوتنسين (مثبطات ACE) ويعمل عن طريق توسيع الأوعية الدموية لديك ليُسهل على القلب ضخ الدم إلى جميع أجزاء الجسم. أما المُكوّن الآخر في كو- رينيتك ، هايدروكلوروثيازيد ، هو دواء ينتمي إلى مجموعة من الأدوية تسمى مدرات البول (أقراص الماء) ويعمل عن طريق جعل الكليتين تُخرج المزيد من المياه والملح. ويساعد كلا المُكوّنين، اينالبريل و هايدروكلوروثيازيد ، معًا على الحد من ارتفاع ضغط الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>رينيتيك لا تتناول كو-</strong> <strong>رينيتك إذا:</strong><br />- كان لديك حساسية نحو اينالبريل ماليات، هايدروكلوروثيازيد ، أو أيّ من المكونات الأخرى في هذا &nbsp;الدواء. وهي مدرجة في الفقرة رقم 6.<br />- سبق و تم علاجك من قبل بأحد الأدوية الأخرى من نفس مجموعة هذا الدواء (مثبطات الإنزيم المحول للأنجيوتنسين) وتعرضت حينها لردود فعل تحسسية على شكل تورم في الوجه والشفتين واللسان و/أو الحلق مع صعوبة في البلع أو التنفس. يجب ألا تستخدم هذا الدواء إذا تعرّضت لهذه الأنواع من ردود الفعل دون سبب معروف، أو إذا سبق وتم تشخيص الوذمة الوعائية الوراثية أو تلك مجهولة السبب لديك.<br />- كنت تعاني من حساسية نحو أي عقاقير مشتقة من السلفوناميد (اسأل طبيبك إذا لم تكن متأكدا من ماهية الأدوية المشتقة من السلفوناميد)<br />- كنت لا تتبوّل ( عدم خروج البول)<br />- كان لديك مشاكل شديدة في الكلى<br />- كان لديك مرض السكري أو ضعف وظائف الكلى وتتعالج بأحد الأدوية الخافضة لضغط الدم الدواء التي تحتوي على أليسكيرن.<br />- تجاوزتِ 3 أشهر الأولى من الحمل. (ومن الأفضل أيضا تجنب كو- رينيتك في المراحل المُبكرة من الحمل - انظري فقرة الحمل)</p><p>&nbsp;</p><p>إذا لم تكن متأكدا مما إذا كان يجب عليك البدء في تناول هذا الدواء، راجع طبيبك.</p><p><strong>المحاذير والإحتياطات</strong><br />تحدث مع طبيبك أو الصيدلي قبل تناول هذا الدواء.<br />- أخبر طبيبك إذا كان لديك أو سبق وتعرّضت لأيّ مشاكل طبية، وكذلك عن أيّ حساسيّة لديك.<br />- إذا كان لديك مشاكل في الكلى، خضعت مؤخرا لزرع الكلى، كنت تخضع لغسيل الكلى، أو تتناول أقراص الماء (مدرات البول).<br />- إذا كان لديك اضطرابات في الدم أو مشاكل في الكبد<br />- إذا كنت تتبع حمية الملح في نظامك الغذائي، أو عانيت من التقيؤ أو الإسهال الشديد مؤخرا<br />- إذا كان لديك حالة مرضية في القلب تُسمى &quot;تضيق الأبهر&quot;، &quot;اعتلال عضلة القلب الضخامي&quot; أو &quot;انسداد موضع تدفق الدم&quot;<br />- إذا كان لديك مرض في كولاجين الأوعية الدموية، أو تتناول الأدوية المُثبّطة للمناعة (تُستخدم في علاج اضطرابات المناعة الذاتية مثل التهاب المفاصل الروماتويدي أو بعد جراحة زرع الأعضاء)<br />- إذا كنت تتناول ألوبيورينول، (المُستخدم في علاج النقرس)، أو بروكايناميد، (يُستخدم في علاج اضطراب ضربات القلب). إذا أُصبت بالعدوى (قد تكون الأعراض ارتفاع في درجة الحرارة أو الحمى)، يجب أن تراجع طبيبك على الفور. قد يأخذ طبيبك عينة من دمك من وقت لآخر للتحقق من عدد خلايا الدم البيضاء<br />- إذا كان لديك تاريخ من الإصابة &nbsp;&quot;بوذمة وعائية&quot; أثناء استخدامك لأدوية أخرى. قد تكون العلامات الحكة، الطفح الجلدي، الصفير أو تورم يديك، الحلق، الفم أو الجفون<br />- إذا كنت مصابا بداء السكري وتتناول أدوية مضادة لمرض السكري، بما في ذلك الأنسولين للسيطرة على مرض السكري (يجب مراقبة مستويات السكر في الدم تحسبا لانخفاضها، وخاصة خلال الشهر الأول من العلاج بهذا الدواء)<br />- إذا كنت تتناول مكملات البوتاسيوم أو الأملاح التي تحتوي على البوتاسيوم<br />- إذا كنت تتناول الليثيوم، الذي يُستخدم في علاج بعض الأمراض النفسية<br />- إذا سبق وأخبرك الطبيب أنك &nbsp;لا تتحمل بعض السكريات.<br />- إذا كنتِ تعتقدين أنك (<u>أو قد تصبحين</u>) حاملا. لا يُنصح باستخدام هذا الدواء في مراحل الحمل الأولى كما يجب ألا يُستخدم بعد تجاوز 3 أشهر الأولى من الحمل، لأنه قد يسبب ضررا خطيرا لطفلك إذا ما استخدم في تلك المرحلة (انظري فقرة الحمل).<br />- أخبر طبيبك إذا كنت تتناول أيًّا من الأدوية التالية المستخدمة في علاج ارتفاع ضغط الدم:</p><p><!--[if !supportLists]-->&sect;&nbsp;&nbsp;&nbsp; <!--[endif]-->حاصرات مستقبلات أنجيوتنسين 2 (ARB) (المعروفة أيضا باسم سارتانز - على سبيل المثال فالسارتان، تلميسارتان، إربيسارتان الخ)، لا سيما إذا كان لديك مشاكل في الكلى مرتبطة بالسكري.</p><p><!--[if !supportLists]-->&sect;&nbsp;&nbsp;&nbsp; <!--[endif]-->أليسكيرن</p><p><!--[if !supportLists]-->&sect;&nbsp;&nbsp;&nbsp; <!--[endif]-->أخبر طبيبك إذا كنت تعاني من انخفاض ضغط الدم (قد تلاحظ ذلك كدوخة أو دوار، خاصة عند الوقوف).</p><p>&nbsp;</p><p>قد يقوم طبيبك بفحص وظائف الكلى، وضغط الدم، ومستوى المعادن (على سبيل المثال، البوتاسيوم) في الدم لديك على فترات منتظمة.</p><p>انظر أيضا المعلومات تحت عنوان &quot;لا تتناول كو- رينيتك &quot;.</p><p>&nbsp;</p><p><strong>إذا کنت علی وشك الخضوع لأي من الإجراءات التالیة، یجب علیك إخبار طبیبك الذي یُعالجك بأنك تتناول &nbsp;كو-</strong> <strong>رينيتك:</strong></p><p>&bull; أي جراحة أو &nbsp;تخضع للتخدير (حتى عند طبيب الأسنان)</p><p>&bull; علاج يسمى فِصادة إل دي إل (البروتينات الدهنيّة منخفضة الكثافة)، لإزالة الكولسترول من الدم باستخدام جهاز معين</p><p>&bull; علاج إزالة التحسّس، للحد من تأثير الحساسية من لسع النحل أو الدبور.</p><p>&nbsp;</p><p><strong>الأطفال والمراهقين</strong></p><p>لم تثبت سلامة وفعالية هذا الدواء لدى الأطفال.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>أدوية أخرى و كو-</strong> <strong>رينيتك</strong></p><p>أخبر طبيبك أو الصيدلي إذا كنت تتناول، قد تناولت مؤخرًا أو قد تتناول أيّ أدوية أخرى. قد يحتاج طبيبك إلى تغيير الجرعة و/أو اتخاذ احتياطات أخرى.</p><p>بشكل عام، يمكن تناول كو- رينيتك بالتزامن مع أدوية أخرى. وكي يصف لك الطبيب الجرعة الصحيحة من كو- رينيتك ، من المهم بشكل خاص أن يعرف إذا كنت تتناول أيّ من الأدوية التالية:<br />&bull; حاصرات مستقبلات الأنجيوتنسين 2 (ARB) أو ألسكيرن (انظر أيضا المعلومات تحت عناوين &#39;لا تتناول كو- رينيتك و &#39;التحذيرات والاحتياطات&#39;)</p><p>&bull; أقراص الماء المــُدرة للبوتاسيوم (مدرات البول) مثل سبیرونولاكتون أو إبلرینون أو تريامترین أو أمايلورايد أو مكملات البوتاسيوم أو بدائل ملحیة تحتوي على البوتاسيوم. كو-رينيتيك قد يزيد من مستويات البوتاسيوم في الدم مما يؤدي إلى ارتفاع مستويات البوتاسيوم. يظهر ذلك من خلال علامات قليلة ويُحدد بفحص البوتاسيوم في الدم،</p><p>&bull; أقراص الماء (مدرات البول) مثل الثيازيدات، فوروسيميد، بوميتانيد،</p><p>&bull; الأدوية الأخرى التي تخفض ضغط الدم، مثل النتروجليسرين والنترات وموسعات الأوعية الدموية، والليثيوم الذي يُستخدم لمعالجة بعض الأمراض النفسية. لا ينبغي تناول كو-رينيتيك مع هذا الدواء.<br />&bull; الباربيتورات (المهدئات المستخدمة في علاج القلق أو الصرع)،</p><p>&bull; مضادات الاكتئاب ثلاثية الحلقات مثل أميتريبتيلين، وتستخدم للاكتئاب، ومضادات الذهان مثل الفينوثيازين، وتستخدم للقلق الشديد،</p><p>&bull; مُسكنات الألم مثل المورفين أو التخدير، لأن ضغط الدم قد ينخفض جدًّا معها،</p><p>&bull; الكولستيرامين أو الكولستيبول (يستخدم للمساعدة في السيطرة على مستويات الكولسترول)،</p><p>&bull; الأدوية المـُــستخدمة للتيبس والالتهابات المرتبطة بالألم، وخاصة تلك التي تؤثر على عضلاتك وعظامك ومفاصلك:</p><p>- بما في ذلك العلاج بالذهب الذي يمكن أن يؤدي إلى احمرار وجهك، والشعور بالمرض (الغثيان)، والتقيؤ وانخفاض ضغط الدم، عند تناوله مع كو- رينيتك ، و</p><p>- العقاقير المضادة للالتهابات غير الستيرويدية (NSAID)، على سبيل المثال ديفلونيسال أو ديكلوفيناك. قد تحد من القدرة في السيطرة على ضغط الدم لديك بشكل جيد ويمكن أن يزيد من مستوى البوتاسيوم في الدم</p><p>&bull; أدوية مثل الإيفيدرين، التي تُستخدم في بعض أدوية السعال والبرد، أو النورادرينالين والأدرينالين التي تُستخدم لعلاج انخفاض ضغط الدم، والصدمة، والفشل القلبي، والربو أو الحساسية. إذا استُخدمت هذه الأدوية مع كو- رينيتك قد تُبقي ضغط الدم عاليًا،</p><p>&bull; إيه سي تي إتش ACTH (لاختبار ما إذا كانت الغدد الكظرية تعمل بشكل صحيح)،</p><p>&bull; الكورتيكوستيرويدات (المستخدمة لعلاج حالات معينة مثل الروماتيزم، والتهاب المفاصل، والحساسية، والربو أو بعض اضطرابات الدم)،</p><p>&bull; ألوبيورينول (يستخدم لعلاج النقرس)،</p><p>&bull; السيكلوسبورين (العوامل المثبطة للمناعة المستخدمة في اضطرابات المناعة الذاتية)،<br />&bull; الأدوية المـُستخدمة في علاج السرطان،</p><p>&bull; مضادات الحموضة (المستخدمة لتخفيف عسر الهضم)،</p><p>&bull; بروكايناميد، أميودارون أو سوتالول (يستخدم لعلاج اضطراب نظم القلب)،</p><p>&bull; الديجيتاليس (يستخدم لعلاج مشاكل ضربات القلب)،</p><p>&bull; كاربينوكسالون (يستخدم لعلاج قرحة المعدة)،</p><p>&bull; الاستخدام المفرط للمليّنات،</p><p>&bull; الأدوية المضادة للسكري مثل الأنسولين. قد يسبب كو- رينيتك انخفاض مستويات سكر الدم أكثر إذا استخدم مع مضادات السكري<br />&bull; مُثبِّط &nbsp;mTOR(على سبيل المثال، تمسيروليموس، سيروليموس، إيفروليموس) لأن الاستخدام المتزامن يمكن أن يزيد من خطر حدوث رد فعل تحسسي يسمى الوذمة الوعائية.</p><p>&nbsp;</p><p><strong>كو-</strong> <strong>رينيتك مع الطعام والشراب</strong></p><p>يمكن تناول كو- رينيتك مع أو بدون الطعام. يتناول معظم الناس كو- رينيتك مع الماء.</p><p>&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية</strong><br /><u>الحمل</u></p><p>إذا كنتِ: حاملًا أو مرضعًا، تعتقدين أنّك قد تكونين حاملًا أو تخططين للحمل، استشيري طبيبك قبل تناول هذا الدواء. سوف ينصحك طبيبك عادة بالتوقف عن تناول كو- رينيتك قبل أن تصبحين حاملًا أو في أقرب وقت تشعرين عنده بالحمل وسيصف لك دواءً آخرَ بدلا من كو- رينيتك. لا يُنصح باستخدام هذا الدواء أثناء الحمل، ويجب عدم تناوله بعد الثلاثة شهور الأولى من الحمل، لأنه قد يسبب ضررًا خطيرًا لطفلك إذا استُخدم بعد الشهر الثالث من الحمل.&nbsp;<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p><u>الرضاعة الطبيعية</u><br />أخبري طبيبك إذا كنت تُرضعين طفلك &nbsp;رضاعة طبيعية أو تعتزمين القيام بذلك. لا يُنصح باستخدام هذا الدواء من قبل الأمهات المُرضعات.</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p>لقد تم الإبلاغ عن بعض &nbsp;الأعراض الجانبية، مثل الدوخة والتعب، أثناء استخدام هذا الدواء مما قد يؤثر على قدرة بعض المرضى على القيادة أو تشغيل الآلات (انظر الأعراض الجانبية المحتملة).</p><p><u>&nbsp;</u></p><p><strong>كو-</strong> <strong>رينيتك يحتوي على اللاكتوز</strong></p><p>كو- رينيتك يحتوي على اللاكتوز، وهو نوع من السكر. إذا سبق وأخبرك طبيبك بأنك تعاني من عدم تحمل لبعض السكريات، فاستشر الطبيب قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سوف يقرر طبيبك الجرعة المناسبة، حسب حالتك وعمَّا إذا كنت تتناول أدوية أخرى.<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p>الجرعة المعتادة هي قرصٌ واحدٌ، يُتناولَ مرةً واحدةً يوميا. إذا لزم الأمر، يمكن زيادة الجرعة إلى قرصين مرة واحدة يوميا. الجرعة القصوى هي قرصين مرة واحدة يوميا. تناول هذا الدواء مع كوب من الماء.</p><p>&nbsp;</p><p>المرضى الذين لديهم تاريخ من مشاكل الكلى قد يحتاجون جرعة أقل من هذا الدواء.</p><p>&nbsp;</p><p>العلاج المـُـسبق بمدرات البول يجب أن يتوقف قبل بدء استخدام هذا الدواء بمدة 2-3 يوم.</p><p><strong>&nbsp;</strong></p><p>تناول هذا الدواء دائما حسب ارشادات الطبيب أو الصيدلي تمامًا. تحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد. من المهم جدا الاستمرار في تناول هذا الدواء طالما وصفه الطبيب. لا تتناول أكثر من الجرعة الموصوفة لك<strong>.</strong></p><p><strong>&nbsp;</strong></p><p><strong>إذا تناولت من كو-</strong> <strong>رينيتك أكثر مما يجب</strong></p><p>في حالة تناوُل جرعة زائدة، اتصل بطبيبك فورًا حتى يمكنه تقديم العناية الطبية لك على وجه السرعة. والأعراض الأكثر احتمالًا أن تحدث هي الشعور بدوخة أو دوار بسبب الانخفاض المفاجئ أو المفرط في ضغط الدم، والعطش المفرط، والسعال، والارتباك، والتنفس السريع، والقلق، وانخفاض في كمية البول الذي تُخرجه، أو سرعة أو بطئ في معدل ضربات القلب.</p><p><strong>&nbsp;</strong></p><p><strong>إذا نسيت أن تتناول كو-</strong> <strong>رينيتك</strong></p><p>يجب تناول هذا الدواء كما وُصف لك. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.<br />واستأنف تناول الدواء حسب الجدول الزمني المعتاد بالنسبة لك.</p><p>&nbsp;</p><p><strong>إذا توقفت عن تناول كو-</strong> <strong>رينيتك</strong></p><p>لا تتوقف عن تناول الدواء ما لم يخبرك الطبيب بذلك.</p><p>&nbsp;</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل سائر الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، وإن كانت لا تحدث لدى جميع من يتناوله.&nbsp;<br /><br />وتستخدم المصطلحات التالية لوصف وتيرة حدوث الأعراض الجانبية التي تم الإبلاغ عنها.</p><p>شائعة جدا (تحدث لدى مريض واحد على الأقل من بين 10 مرضى تم علاجهم )</p><p>شائعة (تحدث لدى مريض واحد على الأقل من بين 100 وأقل من 1 من بين 10 مرضى &nbsp;تم علاجهم)<br />غير شائعة (تحدث لدى &nbsp;مريض واحد على الأقل من بين 1000 وأقل من 1 من بين 100 مريض تم علاجهم )<br />نادرة (تحدث لدى&nbsp; مريض واحد على الأقل من بين 10،000 وأقل من 1 من بين 1000 مريض تم علاجهم )</p><p>نادرة جدا (تحدث في أقل من 1 من بين 10،000 مريض تم علاجهم )</p><p>غير معروفة (لا يمكن تقدير وتيرة الحدوث من البيانات المتاحة)<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p><strong>اضطرابات الدم:</strong></p><p>غير شائعة: فقر الدم (بما في ذلك اللاتنسجي وانحلال الدم)</p><p>نادرة: التغيرات في قيم مكونات الدم مثل انخفاض عدد خلايا الدم البيضاء والحمراء، وانخفاض الهيموجلوبين، وانخفاض عدد الصفائح الدموية، وتورم الغدد في الرقبة والإبط أو الفخذ.</p><p>&nbsp;</p><p><strong>اضطرابات الجهاز المناعي</strong></p><p>نادرة: رد فعل تحسسي مفاجىء ومُهدد للحياة</p><p>&nbsp;</p><p><strong>اضطرابات الغدد الصماء:</strong></p><p>غير معروفة: الإفراط في إنتاج الهرمون المضاد لإدرار البول، والذي يسبب احتباس السوائل، مما يؤدي إلى الضعف، التعب أو الارتباك</p><p>&nbsp;</p><p><strong>اضطرابات الأيض والتغذية</strong></p><p>الشائعة: انخفاض مستويات البوتاسيوم في الدم، وزيادة مستويات الكولسترول أو الدهون في الدم، وارتفاع مستويات حمض اليوريك في الدم</p><p>غير شائعة: انخفاض نسبة السكر في الدم (نقص السكر في الدم)، وانخفاض مستويات المغنيسيوم (نقص مغنيزيوم الدم)، والمرض الناجم عن ترسب بلورات حمض اليوريك (النقرس) * مع تورّم وألم المفاصل، كمية غير عادية من الملح في الجسم (اضطراب في مستوى المعادن في الدم، بما في ذلك نقص الصوديوم)</p><p>نادرة: زيادة في نسبة السكر في الدم</p><p>نادرة جدا: مستويات عالية من الكالسيوم في الدم (فرط كالسيوم الدم)</p><p>&nbsp;</p><p><strong>الجهاز العصبي والاضطرابات النفسية</strong></p><p>شائعة: الصداع، والاكتئاب، والإغماء (الغشيان)، وتغيير في حاسة التذوق</p><p>غير شائعة: الارتباك، والنعاس، والأرق، والعصبية، وخز دون سبب (تنمل)، والإحساس بدوخة (الدوار)، وتدني في الرغبة الجنسية (الرغبة الجنسية) *</p><p>نادرة: الأحلام الغريبة، ومشاكل النوم، وضعف العضلات في بعض الأحيان بسبب انخفاض البوتاسيوم (شلل جزئي)</p><p>&nbsp;</p><p><strong>اضطرابات العين</strong></p><p>شائعة جدا: عدم وضوح الرؤية</p><p>&nbsp;</p><p><strong>اضطرابات الأذن</strong><br />غير شائعة: رنين في الأذنين (طنين)</p><p>&nbsp;</p><p><strong>اضطرابات القلب والأوعية الدموية</strong></p><p>شائعة جدا: الدوخة</p><p>شائعة: انخفاض في ضغط الدم (انخفاض ضغط الدم)، والشعور بالدوار بسبب انخفاض ضغط الدم (بما في ذلك انخفاض في ضغط الدم عند الوقوف بسرعة)، والذبحة الصدرية أو ألم في الصدر، والتغيير في إيقاع القلب، وسرعة ضربات القلب</p><p>غير شائعة: احمرار الوجه، تسارع ضربات القلب أو عدم انتظامها (الخفقان)، والنوبات القلبية، والسكتة الدماغية ربما بسبب الانخفاض الشديد في ضغط الدم لدى المرضى المـُـعرّضين لذلك بشكل كبير (المرضى الذين يعانون من اضطرابات تدفق الدم في القلب و/أو الدماغ)</p><p>نادرة: ضعف تدفق الدم في الأطراف (ظاهرة رينود)</p><p>&nbsp;</p><p><strong>أمراض الجهاز التنفسي والصدر </strong><br />شائعة جدا: السعال</p><p>شائعة: ضيق في التنفس (ضيق التنفس)</p><p>غير شائعة: سيلان الأنف (سيلان الأنف)، والتهاب الحلق وبحة في الصوت، وضيق الصدر المرتبط بالربو</p><p>نادرة: ارتشاحات (ارتشاحات موضعية في الرئتين)، الضائقة التنفسية بما في ذلك التهاب الرئتين (التهاب رئوي) وتراكم السوائل أو غيرها من المواد في الرئتين (وذمة رئوية) (كما يظهر من خلال الأشعة السينية)، التهاب الأنف (التهاب الأنف )، والتهاب الحويصلات الهوائية في الرئتين (التهاب الحويصلات الهوائية التحسسي)، والالتهاب الرئوي (الالتهاب الرئوي اليوزيني)</p><p>&nbsp;</p><p><strong>اضطرابات الجهاز الهضمي</strong></p><p>شائع جدا: الغثيان</p><p>شائعة: الإسهال، آلام في البطن</p><p>غير شائعة: بطء حركة الطعام خلال الأمعاء (العلوص = انسداد الأمعاء)، التهاب البنكرياس (التهاب البنكرياس)، التقيؤ، عسر الهضم (صعوبة الهضم)، الإمساك، فقدان الشهية (فقدان الشهية للطعام)، آلام في المعدة وتهيج، جفاف الفم، قرحة في المعدة (معدية) و قرحة المعوية (تقرح الأمعاء)، وانتفاخ البطن *</p><p>نادرة: قروح الفم (التهاب الفم/التقرح القلاعي)، تورم اللسان (التهاب اللسان)<br />نادرة جدا: تورم في الأمعاء (وذمة وعائية في الأمعاء)</p><p>&nbsp;</p><p><strong>اضطرابات كبدية-صفراوية </strong></p><p>نادرة: اختلال وظائف الكبد والتهاب الكبد (التهاب الكبد) مع تدمير خلايا الكبد واليرقان (تلون العينين أو الجلد باللون الأصفر) ، ومشاكل المرارة (التهاب المرارة)</p><p>&nbsp;</p><p><strong>اضطرابات الجلد والأنسجة تحت الجلد</strong></p><p>شائعة: طفح جلدي (طفح جلدي)، الحساسية مع تورم في الوجه، الشفاه، اللسان، و/أو الحلق مع صعوبة في البلع أو التنفس</p><p>غير شائعة: زيادة التعرق (تعرّق شديد)، والحكة (حكة)، الشرى (أرتيكاريا)، وتساقط الشعر (ثعلبة)، وزيادة حساسية الجلد لأشعة الشمس</p><p>نادرة: الطفح الجلدي الذي يبدو وكأنه أهداف (حمامي عديدة الأشكال)، رد فعل تحسّسيّ شديد مع ارتفاع في درجة الحرارة، متلازمة ستيفنز جونسون والانحلال البشرة السامة (حالة شديدة تُصيب الجلد مع احمرار، وتقشر وتبثّر الجلد)، طفح جلدي شديد مع فقدان الجلد والشعر (التهاب الجلد التقشري)، والبقع الأرجوانية أو الحمراء على الجلد (فرفرية)، الذئبة الحمامية الجلدية (مرض ذاتي المناعة)، الطفح الجلدي الأحمر مع تقشير الجلد (إحمرار الجلد)، نتوءات صغيرة مليئة بالسوائل على الجلد (الفقاع)</p><p>&nbsp;</p><p>غير معروفة: لقد تم الإبلاغ عن مجموعة من الأعراض التي قد تشمل بعض أو كل ما يلي: الحمى، والتهاب الأوعية الدموية (التهاب المصليّة/التهاب الأوعية الدموية)، وآلام في العضلات (ألم عضل/التهاب العضل)، وآلام المفاصل (ألم مفصلي/التهاب مفصلي). قد يحدث طفح جلدي أو أعراض جلدية أخرى.</p><p>&nbsp;</p><p><strong>الاضطرابات العضلية الهيكلية والنسيج الضام</strong></p><p>شائعة: تقلصات العضلات **<br />غير شائعة: آلام المفاصل (ألم مفصلي) *</p><p>&nbsp;</p><p><strong>اضطرابات الكلى والجهاز البولي </strong></p><p>غير شائعة: مشاكل في الكلى (خلل في وظيفة الكلى)، الفشل الكلوي، وظهور البروتين في البول (فقدان البروتين في البول)، والسكر في البول (ظهور السكر في البول)</p><p>نادرة: انخفاض كمية البول (قلة البول)، وأمراض الكلى (التهاب الكلية الخلالي)</p><p>&nbsp;</p><p><strong>الجهاز التناسلي واضطرابات الثدي</strong></p><p>غير شائعة: العجز الجنسي</p><p>نادرة: تضخّم الثدي عند الرجال (تضخم ثدي الرجل)<br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p><p><strong>الاضطرابات العامة وحالة موضع تناول الدواء</strong></p><p>شائعة جدا: الضعف (الوهن)<br />شائعة: ألم في الصدر، والتعب</p><p>غير شائعة: الشعور بالتوعك (الشعور بالضيق) والحمى</p><p>&nbsp;</p><p><strong>الفحوص المِخبريّة </strong></p><p>شائعة: مستويات عالية من البوتاسيوم في الدم (فرط بوتاسيوم الدم)، والتي قد تظهر على شكل تشنجات العضلات، وارتفاع مستوى الكرياتينين في الدم، والإسهال، والغثيان، والدوخة والصداع</p><p>غير شائعة: ارتفاع مستوى اليوريا في الدم، وانخفاض مستوى الصوديوم في الدم<br />نادرة: ارتفاع في مستويات إنزيمات الكبد أو البيليروبين.</p><p>&nbsp;</p><p>قد تحدث أيضا أعراض أخرى بشكل غير شائع أو نادر، وبعضها قد يكون خطرا. اسأل طبيبك أو الصيدلي عن مزيد من المعلومات حول الأعراض الجانبية. لدى كل من الطبيب والصيدلي قائمة أكثر شمولية عن الأعراض الجانبية.</p><p>&nbsp;</p><p>أخبر طبيبك أو الصيدلي فورًا عن هذه أو أيّ أعراضٍ أخرى غير عادية.</p><p>&nbsp;</p><p>توقف عن تناول كو-رينيتيك واتصل بطبيبك فورًا عند تعرضك لأي من الحالات التالية:</p><p>&bull; إذا تعرّضت لتورم في الوجه والشفتين واللسان و/أو الحلق مما قد يسبب صعوبة في التنفس أو البلع</p><p>&bull; إذا واجهت تورم في اليدين أو القدمين أو الكاحلين</p><p>&bull; إذا تعرّضت للشرى.</p><p>&nbsp;</p><p>قد تسبب الجرعة الابتدائيّة انخفاضًا أكبرَ في ضغط الدم مقارنة بالجرعات التالية مع استمرار العلاج. قد تلاحظ هذا كضعف أو دوار وقد يساعدك الاستلقاء على التقليل أو التخلص من تلك الأعراض . إذا استلزم الأمر، يرجى استشارة الطبيب.</p><p>&nbsp;</p><p>* تحدث فقط مع جرعات من هايدروكلوروثيازيد 12.5 ملغم و 25 ملغم</p><p>** تواتر تشنجات العضلات على أنه شائع&nbsp; يتعلق بجرعات من هايدروكلوروثيازيد 12.5 ملغم و 25 ملغم ، في حين أن تواترها على أنه غير شائع يتعلق بجرعات 6 ملغم من هايدروكلوروثيازيد .</p><p>&nbsp;</p><p><strong>الإبلاغ عن </strong>الأعراض <strong>الجانبية</strong></p><p>إذا تعرّضت لأي أعراض جانبية، تحدث مع طبيبك أو الصيدلي. ويشمل ذلك أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة عن طريق (المركز الوطني للتيقظ &nbsp;والسلامة الدوائية التابع للهيئة العامة للغذاء والدواء ) . من خلال الإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p><p><br /><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال<br />يُحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p>يُحفظ في علبته الأصلية</p><p>لا يجوز إستخدام هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العُلبة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p>&nbsp;</p><p>لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. وستساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ماذايحتوي كو-</strong> <strong>رينيتك </strong></p><p>&bull; المواد الفعالة هي اينالبريل ماليات (20 ملغم ) و&nbsp; هايدروكلوروثيازيد &nbsp;(12.5 ملغم )</p><p>&bull; المكونات الأخرى هي بيكربونات الصوديوم، اللاكتوز المائي، نشا الذرة، النشا المُسبق التجلتن، ستيراتالمغنيسيوم (E572). وقد &nbsp;يُستخدم أكسيد الحديد الأصفر (E172) كعامل مُلوّن.</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص كو- رينيتك هي صفراء، مستديرة، مخدّدة الشكل، نُقش على جانب واحد منها رمز &quot;MSD 718&quot; والجانب الآخر مُحزّز. أحجام العبوات: علبة تحتوي على ثلاث شرائط يضم كلٍ منها 10 أقراص، وعلبة تحتوي على شريطين يضمّان 14 قرصًا. قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong>ميرك شارب و دوم بي في، واردرويج 39،</p><p>2031 بي إن هارلم، صندوق بريد 581، 2003 بي سي هارلم،</p><p>هولندا</p><p>&nbsp;</p><p><strong>الشركة الصانعة:</strong></p><p>ميرك شارب و دوم المحدودة&nbsp; شوتون لين ،</p><p>كراملينجتون ، نورثمبرلاند إن إي ٢٣ ٣جي يو<br />المملكة المتحدة.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة بتاريخ {تموز / يوليو 2016م{رقم النسخة : الإصدار رقم (02)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CO-RENITEC 20 mg/12.5 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 20 mg of enalapril maleate and 12.5 mg of hydrochlorothiazide. Excipient(s) with known effect:
One tablet contains 141 mg of lactose hydrous.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets.

Yellow, round, fluted shaped tablets, with on one side ‘MSD 718’ and the other side scored.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of hypertensive patients who have insufficiently responded to treatment with enalapril or a diuretic as a single therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Posology</u></p><p>&nbsp;</p><p><em>Hypertension</em></p><p>The usual dosage is one tablet, administered once daily . If necessary the dose may be increased to two tablets, administered once daily. The maximum dosage is two tablets, administered once daily.</p><p>&nbsp;</p><p><em>Prior</em><em> </em><em>Diuretic</em><em> </em><em>Therapy</em></p><p>Symptomatic hypotension may occur following the initial dose of CO-RENITEC; this is more likely in patients who are volume- or salt-depleted as a result of prior diuretic therapy. Therefore, diuretic therapy should be discontinued for 2-3 days prior to initiation of therapy with CO-RENITEC (see section 4.4).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><em>Dosage</em><em> </em><em>in</em><em> </em><em>Renal</em><em> </em><em>Insufficiency</em></p><p>Since the initial dose of enalapril in mild renal impairment (creatinine clearance greater than 30 ml/min to less than 80 ml/min) is 5-10 mg, CO-RENITEC is not recommended as initial therapy in these patients (see section 4.4).</p><p>CO-RENITEC should not be administered to these patients until after titration of the individual components.</p><p>CO-RENITEC is contraindicated in patients who have a creatinine clearance less than or equal to 30 ml/min.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>CO-RENITEC is not recommended for use in children below 18 years of age due to a lack of data on safety and efficacy.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Severe renal impairment (creatinine clearance ≤30 ml/min).
•	Anuria.
•	History of angioneurotic oedema associated with previous ACE-inhibitor therapy.
•	Hereditary or idiopathic angioedema.
•	Hypersensitivity to sulfonamide-derived drugs.
•	Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
•	Severe hepatic impairment.
•	The concomitant use of CO-RENITEC with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73m2) (see sections 4.5 and 5.1).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Enalapril Maleate-Hydrochlorothiazide</u></p><p><u>Hypotension and Electrolyte Fluid Imbalance</u></p><p>Symptomatic hypotension is rarely seen in uncomplicated hypertensive patients. In hypertensive patients receiving CO-RENITEC, symptomatic hypotension is more likely to occur if the patient has been volume-depleted, e.g. by diuretic therapy, dietary salt restriction, diarrhoea or vomiting (see sections 4.5 and 4.8). Regular determination of serum electrolytes should be performed at appropriate intervals in such patients. Special attention should be paid to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident</p><p>&nbsp;</p><p>If hypotension occurs, the patient should be placed in the supine position and, if necessary, should &nbsp;receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses, which can be given usually without difficulty once the blood pressure has increased after volume expansion.</p><p>&nbsp;</p><p>In some patients with heart failure who have normal or low blood pressure, additional lowering of systemic blood pressure may occur with CO-RENITEC. This effect is anticipated, and usually is not a reason to discontinue treatment. If hypotension becomes symptomatic, a reduction of dose and/or discontinuation of the diuretic and/or CO-RENITEC may be necessary</p><p>In hypertensive patients with heart failure, with or without associated renal insufficiency, symptomatic hypotension has been observed. This is most likely to occur in those patients with more severe degrees of heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia or functional renal impairment. In these patients, therapy should be started under medical supervision and the patients should be followed closely whenever the dose of CO-RENITEC and/or diuretic is adjusted. Similar considerations may apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.</p><p>&nbsp;</p><p><u>Renal Function Impairment</u></p><p>CO-RENITEC should not be administered to patients with renal insufficiency (creatinine clearance &lt; 80 ml/min and &gt; 30 ml/min) until titration with the individual components has shown the need for the dose present in this formulation (see section 4.2).</p><p>&nbsp;</p><p>Some hypertensive patients with no apparent pre-existing renal disease have developed increases in blood urea and creatinine when enalapril has been given concurrently with a diuretic (see section 4.4). If this occurs, therapy with CO-RENITEC should be discontinued. This situation should raise the possibility of underlying renal artery stenosis (see section 4.4).</p><p>&nbsp;</p><p>Renal failure has been reported in association with enalapril and has been mainly in patients with severe heart failure or underlying renal disease, including renal artery stenosis. If recognised promptly and treated appropriately, renal failure when associated with therapy with enalapril is usually reversible</p><p>&nbsp;</p><p><u>Dual blockade of the reinin-angiotensin-aldosterone system (RAAS)</u></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia, and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>&nbsp;</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p><u>Hyperkalaemia</u></p><p>The combination of enalapril and a low-dose diuretic cannot exclude the possibility of a hyperkalaemia to occur (see section 4.4).</p><p>&nbsp;</p><p><u>Lithium</u></p><p>The combination of lithium with enalapril and diuretic agents is generally not recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Lactose</u></p><p>CO-RENITEC contains less than 200 mg of lactose per tablet. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p><u>Enalapril Maleate</u></p><p><strong>&nbsp;</strong></p><p><u>Aortic Stenosis/Hypertrophic Cardiomyopathy</u></p><p>As with all vasodilators, ACE inhibitors should be given with caution to patients with left ventricular valvular outflow tract obstruction and avoided in cases of cardiogenic shock and haemodynamically significant obstruction.</p><p>&nbsp;</p><p><u>Renal Function Impairment</u></p><p>Renal failure has been reported in association with enalapril and has been mainly in patients with severe heart failure or underlying renal disease, including renal artery stenosis. If recognised promptly and treated appropriately, renal failure when associated with therapy with enalapril is usually reversible (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><u>Renovascular Hypertension</u></p><p>There is an increased risk of hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with ACE inhibitors. Loss of renal function may occur with only mild changes in serum creatinine. In these patients, therapy should be initiated under close medical supervision with low doses, careful titration and monitoring of renal function.</p><p>&nbsp;</p><p><u>Kidney Transplantation</u></p><p>There is no experience regarding the administration of enalapril in patients with a recent kidney transplantation. Treatment with enalapril is therefore not recommended.</p><p>&nbsp;</p><p><u>Haemodialysis Patients</u></p><p>The use of enalapril is not indicated in patients requiring dialysis for renal failure. Anaphylactoid reactions have been reported in patients dialysed with high-flux membranes (e.g., AN 69&reg;) and treated concomitantly with an ACE inhibitor. In these patients consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.</p><p>&nbsp;</p><p><u>Hepatic Failure</u></p><p>Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice or hepatitis and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up (see section 4.4).</p><p>&nbsp;</p><p><u>Neutropenia/Agranulocytosis</u></p><p>Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely. Enalapril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections which in a few instances did not respond to intensive antibiotic therapy. If enalapril is used in such patients, periodic monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection.</p><p>&nbsp;</p><p><u>Hyperkalaemia</u></p><p>Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including enalapril. Risk factors for the development of hyperkalaemia include those with renal insufficiency, worsening of renal function, age (&gt; 70 years), diabetes mellitus, intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis and concomitant use of potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene or amiloride), potassium supplements or potassium-containing salt substitutes; or those patients taking other drugs associated with increases in serum potassium (e.g., heparin). The use of potassium supplements, potassium- sparing diuretics or potassium-containing salt substitutes particularly in patients with impaired renal function may lead to a significant increase in serum potassium. Hyperkalaemia can cause serious, sometimes fatal arrhythmias. If concomitant use of CO-RENITEC and any of the above-mentioned agents is deemed appropriate, they should be used with caution and with frequent monitoring of serum potassium (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><u>Hypoglycaemia</u></p><p>Diabetic patients treated with oral antidiabetic agents or insulin starting an ACE inhibitor should be told to closely monitor for hypoglycaemia, especially during the first month of combined use (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><u>Hypersensitivity/Angioneurotic Oedema</u></p><p>Angioneurotic oedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors, including enalapril maleate. This may occur at any time during treatment. In such cases, CO-RENITEC should be discontinued promptly and appropriate monitoring should be instituted to ensure complete resolution of symptoms prior to dismissing the patient. Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient.</p><p>&nbsp;</p><p>Very rarely, fatalities have been reported due to angioedema associated with laryngeal oedema or tongue oedema. Patients with involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy which may include &nbsp;subcutaneous epinephrine solution 1:1000 (0.3 ml to 0.5 ml) and/or measures to ensure a patent airway, should be administered promptly.</p><p>&nbsp;</p><p>Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. However, in general it appears that black people have an increased risk for angioedema.</p><p>&nbsp;</p><p>Patients with a history of angiooedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see also section 4.3).</p><p>&nbsp;</p><p>Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.</p><p>&nbsp;</p><p><u>Anaphylactoid Reactions during Hymenoptera Desensitisation</u></p><p>Rarely, patients receiving ACE inhibitors during desensitisation with hymenoptera venom have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each desensitisation.</p><p>&nbsp;</p><p><u>Anaphylactoid Reactions during LDL-Apheresis</u></p><p>Rarely, patients receiving ACE inhibitors during low density lipoprotein (LDL)-apheresis with dextran sulphate have experienced life-threatening anaphylactic reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.</p><p>&nbsp;</p><p><u>Cough</u></p><p>Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is nonproductive, persistent, and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.</p><p>&nbsp;</p><p><u>Surgery/Anaesthesia</u></p><p>Enalapril blocks angiotensin II formation and therefore impairs the ability of patients undergoing major surgery or anaesthesia with agents that produce hypotension to compensate via the renin-angiotensin system. Hypotension which occurs due to this mechanism can be corrected by volume expansion (see section 4.5).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>&nbsp;</p><p><u>Ethnic Differences</u></p><p>As with other angiotensin converting enzyme inhibitors, enalapril is apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.</p><p>&nbsp;</p><p><u>Hydrochlorothiazide</u></p><p><strong>&nbsp;</strong></p><p><u>Renal Function Impairment</u></p><p>Thiazides may not be appropriate diuretics for use in patients with renal impairment, and are ineffective at creatinine clearance values of 30 ml/min or below (i.e., moderate or severe renal insufficiency) (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><u>Hepatic Disease</u></p><p>Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma (see section 4.4).</p><p>&nbsp;</p><p><u>Metabolic and Endocrine Effects</u></p><p>Thiazide therapy may impair glucose tolerance. Dosage adjustment of antidiabetic agents, including insulin, may be required (see section 4.4).</p><p>&nbsp;</p><p>Increases in cholesterol and triglyceride levels may be associated with thiazide diuretic therapy; however, at the 12.5 mg dose of hydrochlorothiazide, minimal or no effect was reported.</p><p>&nbsp;</p><p>Thiazide therapy has been associated with the development of hyperuricaemia and/or gout in certain patients. In addition, enalapril may increase urinary uric acid and thus attenuate the hyperuricaemic effect of hydrochlorothiazide.</p><p>&nbsp;</p><p>As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.</p><p>&nbsp;</p><p>Thiazides (including hydrochlorothiazide) can cause fluid or electrolyte imbalance (hypokalaemia, hyponatraemia, and hypochloraemic alkalosis). Warning signs of fluid or electrolyte imbalance are xerostomia, thirst, weakness, lethargy, somnolence, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.</p><p>&nbsp;</p><p>Although hypokalaemia may develop during use of thiazide diuretics, concurrent therapy with enalapril may reduce diuretic-induced hypokalaemia. The risk of hypokalaemia is greatest in patients with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients with inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or ACTH (see section 4.5).</p><p>&nbsp;</p><p>Hyponatraemia may occur in oedematous patients in hot weather. Chloride deficit is generally mild and does usually not require treatment.</p><p>&nbsp;</p><p>Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcaemia may be evidence of latent hyperparathyroidism. Thiazides should be discontinued before testing parathyroid function.</p><p>&nbsp;</p><p>Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>In patients receiving thiazides, sensitivity reactions may occur with or without a history of allergy or bronchial asthma. Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazides.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Anti-doping test: </u></p><p>Hydrochlorothiazide contained in this product can produce a positive analytic result in an anti-doping test</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if !supportLists]-->2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Enalapril Maleate-Hydrochlorothiazide</u></p><p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>Clinical trial data have shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p>&nbsp;</p><p><u>Other Antihypertensive Agents</u></p><p>Concomitant use of these agents may increase the hypotensive effects of enalapril and hydrochlorothiazide. Concomitant use with nitroglycerine and other nitrates, or other vasodilators, may further reduce blood pressure.</p><p>&nbsp;</p><p><u>Lithium</u></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide diuretics may further increase lithium levels and enhance the risk of lithium toxicity with ACE inhibitors.</p><p>&nbsp;</p><p>Use of CO-RENITEC with lithium is not recommended, but if the combination proves necessary, careful monitoring of serum lithium levels should be performed (see section 4.4).</p><p>&nbsp;</p><p><u>Non-Steroidal Anti-inflammatory Drugs Including Selective Cyclooxygenase-2 (COX-2) Inhibitors</u> Non-steroidal anti-inflammatory drugs (NSAIDs) including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors) may reduce the effect of diuretics and other antihypertensive drugs. Therefore, the antihypertensive effect of angiotensin II receptor antagonists, ACE inhibitors or diuretics may be attenuated by NSAIDs including selective COX-2 inhibitors.</p><p>&nbsp;</p><p>The co-administration of NSAIDs (including COX-2 inhibitors) and angiotensin II receptor antagonists or ACE inhibitors exert an additive effect on the increase in serum potassium, and may result in a deterioration of renal function. These effects are usually reversible. Rarely, acute renal failure may occur, especially in patients with compromised renal function (such as the elderly or patients who are volume-depleted, including those on diuretic therapy). Therefore, the combination should be administered with caution in patients with compromised renal function.</p><p>&nbsp;</p><p><u>Enalapril Maleate</u></p><p><strong>&nbsp;</strong></p><p><u>Potassium-sparing Diuretics or Potassium Supplements</u></p><p>ACE inhibitors attenuate diuretic induced potassium loss. Potassium-sparing diuretics (e.g. spironolactone, eplerenone, triamterene or amiloride), potassium supplements, or potassium- containing salt substitutes may lead to significant increases in serum potassium. If concomitant use is indicated because of demonstrated hypokalaemia they should be used with caution and with frequent monitoring of serum potassium (see section 4.4).</p><p>&nbsp;</p><p><u>Diuretics (thiazide or loop diuretics)</u></p><p>Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with enalapril (see sections 4.2 and 4.4). The hypotensive effects can be reduced by discontinuation of the diuretic or by increasing volume or salt intake.</p><p>&nbsp;</p><p><u>Tricyclic Antidepressants/Antipsychotics/Anaesthetics</u></p><p>Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see section 4.4).</p><p>&nbsp;</p><p><u>Sympathomimetics</u></p><p>Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors (see section 4.5).</p><p>&nbsp;</p><p><u>Antidiabetics</u></p><p>Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood-glucose lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><u>Alcohol</u></p><p>Alcohol enhances the hypotensive effect of ACE inhibitors (see section 4.5).</p><p>&nbsp;</p><p><u>Acetyl salicylic acid, Thrombolytics and </u><u>b-blockers</u></p><p>Enalapril can be safely administered concomitantly with acetyl salicylic acid (at cardiologic doses), thrombolytics and b-blockers.</p><p>&nbsp;</p><p><u>Gold</u></p><p>Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including enalapril.</p><p>&nbsp;</p><p><u>Mammalian Target of Rapamycin (mTOR) Inhibitors</u></p><p>Patients taking concomitant mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see section 4.4).</p><p>&nbsp;</p><p><u>Hydrochlorothiazide</u></p><p><strong>&nbsp;</strong></p><p><u>Nondepolarizing Muscle Relaxants</u></p><p>Thiazides may increase the responsiveness to tubocurarine.</p><p>&nbsp;</p><p><u>Alcohol, Barbiturates, or Opioid Analgesics</u></p><p>Potentiation of orthostatic hypotension may occur (see section 4.5).</p><p>&nbsp;</p><p><u>Antidiabetic Drugs (oral agents and insulin)</u></p><p>Dosage adjustment of the antidiabetic drug may be required (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><u>Cholestyramine and Colestipol Resins</u></p><p>Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent respectively.</p><p>&nbsp;</p><p><u>Increasing the QT Interval (e.g., quinidine, procainamide, amiodarone, sotalol)</u> Increased risk of torsades de pointes.</p><p>&nbsp;</p><p><u>Digitalis Glycosides</u></p><p>Hypokalaemia can sensitise or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability).</p><p>&nbsp;</p><p><u>Corticosteroids, ACTH</u></p><p>Intensified electrolyte depletion, particularly hypokalaemia.</p><p>&nbsp;</p><p><u>Kaliuretic Diuretics (e.g., furosemide), Carbenoxolone or Laxative Abuse</u> Hydrochlorothiazide may increase the loss of potassium and/or magnesium.</p><p>&nbsp;</p><p><u>Pressor Amines (e.g., noradrenaline)</u></p><p>The effect of pressor amines may be decreased (see section 4.5).</p><p>&nbsp;</p><p><u>Cytostatics (e.g., cyclophosphamide, methotrexate)</u></p><p>Thiazides may reduce the renal excretion of cytotoxic drugs and potentiate their myelosuppressive effects.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><em>Pregnancy</em></p><p>ACE inhibitors:</p><p>The use of ACE inhibitors is not recommended during the first trimester of pregnancy (see section 4.4). The use of ACE inhibitors is contra-indicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.</p><p>&nbsp;</p><p>When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>&nbsp;</p><p>Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3). Maternal oligohydramnios, presumably representing decreased foetal renal function, has occurred and may result in limb contractures, craniofacial deformations and hypoplastic lung development.</p><p>&nbsp;</p><p>Should exposure to ACE inhibitors have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>&nbsp;</p><p>Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>Hydrochlorothiazide:</p><p>There is limited experience with hydrochlorothiazide during pregnancy especially during the first trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p>&nbsp;</p><p>Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.</p><p>&nbsp;</p><p>Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used.</p><p>&nbsp;</p><p><em>Breast-feeding</em></p><p>Enalapril:</p><p>Limited pharmacokinetic data demonstrate very low concentrations in breast milk (see section 5.2). Although these concentrations seem to be clinically irrelevant, the use of CO-RENITEC in breast-feeding is not recommended for preterm infants and for the first few weeks after delivery, because of the hypothetical risk of cardiovascular and renal effects</p><p>and because there is not enough clinical experience. In the case of an older infant, the use</p><p>of CO-RENITEC in a breast-feeding mother may be considered if this treatment is necessary for the mother and the child is observed for any adverse effect.</p><p>&nbsp;</p><p>Hydrochlorothiazide:</p><p>Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit the milk production. The use of CO-RENITEC</p><p>during breast-feeding is not recommended. If CO-RENITEC is used during breast-feeding, doses should be kept as low as possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CO-RENITEC is usually well-tolerated. In clinical studies, side effects have usually been mild and transient, and in most instances have not required interruption of therapy.</p><p>&nbsp;</p><p>The most common side effects reported during clinical study with CO-RENITEC were headache and cough.</p><p>&nbsp;</p><p>The following undesirable side effects have been reported with CO-RENITEC, enalapril alone or hydrochlorothiazide alone, either during clinical studies or after the drug was marketed:</p><p>&nbsp;</p><p>Table 1. Undesirable effects of CO-RENITEC</p><table style="width:653px" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:35.4pt; vertical-align:top; width:87.5pt"><p><strong>System</strong><strong> </strong><strong>organ class</strong></p></td><td style="border-color:black; height:35.4pt; vertical-align:top; width:53.65pt"><p><strong>Very common (&ge;1/10)</strong></p></td><td style="border-color:black; height:35.4pt; vertical-align:top; width:66.85pt"><p><strong>Common</strong><strong> </strong><strong>(&ge;1/100 to</strong></p><p><strong>&lt;1/10)</strong></p></td><td style="border-color:black; height:35.4pt; vertical-align:top; width:1.0in"><p><strong>Uncommon</strong><strong> </strong><strong>(&ge;1/1,000 to</strong></p><p><strong>&lt;1/100)</strong></p></td><td style="border-color:black; height:35.4pt; vertical-align:top; width:1.0in"><p><strong>Rare (&ge;1/10,000 to</strong></p><p><strong>&lt;1/1,000)</strong></p></td><td style="border-color:black; height:35.4pt; vertical-align:top; width:63.0pt"><p><strong>Very rare (&lt;1/10,000)</strong></p></td><td style="border-color:black; height:35.4pt; vertical-align:top; width:75.1pt"><p><strong>Not known (cannot be estimated from the available data)</strong></p></td></tr><tr><td style="border-color:black; height:200.4pt; vertical-align:top; width:87.5pt"><p><strong><em>Blood and lymphatic system disorders</em></strong></p></td><td style="height:200.4pt; vertical-align:top; width:53.65pt"><p>&nbsp;</p></td><td style="height:200.4pt; vertical-align:top; width:66.85pt"><p>&nbsp;</p></td><td style="height:200.4pt; vertical-align:top; width:1.0in"><p>Anaemia (including aplastic and haemolytic)</p></td><td style="height:200.4pt; vertical-align:top; width:1.0in"><p>Neutropenia, decreases in haemoglobin, decreases in haematocrit, thrombo- cytopenia, agranulo- cytosis, bone marrow depression, leukopenia, pancytopenia, lymphadeno- pathy, autoimmune diseases</p></td><td style="height:200.4pt; vertical-align:top; width:63.0pt"><p>&nbsp;</p></td><td style="height:200.4pt; vertical-align:top; width:75.1pt"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table style="width:677px" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:35.4pt; vertical-align:top; width:87.5pt"><p><strong>System</strong><strong> </strong><strong>organ class</strong></p></td><td style="border-color:black; height:35.4pt; vertical-align:top; width:53.65pt"><p><strong>Very common (&ge;1/10)</strong></p></td><td style="border-color:black; height:35.4pt; vertical-align:top; width:66.85pt"><p><strong>Common</strong><strong> </strong><strong>(&ge;1/100 to</strong></p><p><strong>&lt;1/10)</strong></p></td><td style="border-color:black; height:35.4pt; vertical-align:top; width:1.0in"><p><strong>Uncommon</strong><strong> </strong><strong>(&ge;1/1,000 to</strong></p><p><strong>&lt;1/100)</strong></p></td><td style="border-color:black; height:35.4pt; vertical-align:top; width:1.0in"><p><strong>Rare (&ge;1/10,000 to</strong></p><p><strong>&lt;1/1,000)</strong></p></td><td style="border-color:black; height:35.4pt; vertical-align:top; width:63.0pt"><p><strong>Very rare (&lt;1/10,000)</strong></p></td><td style="border-color:black; height:35.4pt; vertical-align:top; width:93.0pt"><p><strong>Not known (cannot be estimated from the available data)</strong></p></td></tr><tr><td style="border-color:black; height:59.3pt; vertical-align:top; width:87.5pt"><p><strong><em>Endocrine</em></strong><strong><em> </em></strong><strong><em>disorders</em></strong></p></td><td style="height:59.3pt; vertical-align:top; width:53.65pt"><p>&nbsp;</p></td><td style="height:59.3pt; vertical-align:top; width:66.85pt"><p>&nbsp;</p></td><td style="height:59.3pt; vertical-align:top; width:1.0in"><p>&nbsp;</p></td><td style="height:59.3pt; vertical-align:top; width:1.0in"><p>&nbsp;</p></td><td style="height:59.3pt; vertical-align:top; width:63.0pt"><p>&nbsp;</p></td><td style="height:59.3pt; vertical-align:top; width:93.0pt"><p>Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</p></td></tr><tr><td style="border-color:black; height:129.85pt; vertical-align:top; width:87.5pt"><p><strong><em>Metabolism</em></strong><strong><em> </em></strong><strong><em>and nutrition disorders</em></strong></p></td><td style="height:129.85pt; vertical-align:top; width:53.65pt"><p>&nbsp;</p></td><td style="height:129.85pt; vertical-align:top; width:66.85pt"><p>Hypo- kalaemia, increase of cholesterol, increase of triglycerides, hyper- uricaemia</p></td><td style="height:129.85pt; vertical-align:top; width:1.0in"><p>Hypo- glycaemia (see section 4.4), hypo- magnesaemia, gout**, electrolyte imbalance (including hypo- natraemia)</p></td><td style="height:129.85pt; vertical-align:top; width:1.0in"><p>Increase in blood glucose</p></td><td style="height:129.85pt; vertical-align:top; width:63.0pt"><p>Hyper- calcaemia (see section 4.4)</p></td><td style="height:129.85pt; vertical-align:top; width:93.0pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:106.3pt; vertical-align:top; width:87.5pt"><p><strong><em>Nervous</em></strong><strong><em> </em></strong><strong><em>system</em></strong><strong><em> </em></strong><strong><em>and psychiatric disorders</em></strong></p></td><td style="height:106.3pt; vertical-align:top; width:53.65pt"><p>&nbsp;</p></td><td style="height:106.3pt; vertical-align:top; width:66.85pt"><p>Headache, depression, syncope, taste alteration</p></td><td style="height:106.3pt; vertical-align:top; width:1.0in"><p>Confusion, somnolence, insomnia, nervousness, paresthesia, vertigo, decreased libido**</p></td><td style="height:106.3pt; vertical-align:top; width:1.0in"><p>Dream abnormality, sleep disorders, paresis (due to hypokalaemia)</p></td><td style="height:106.3pt; vertical-align:top; width:63.0pt"><p>&nbsp;</p></td><td style="height:106.3pt; vertical-align:top; width:93.0pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:23.75pt; vertical-align:top; width:87.5pt"><p><strong><em>Ear and labyrinth disorders</em></strong></p></td><td style="height:23.75pt; vertical-align:top; width:53.65pt"><p>&nbsp;</p></td><td style="height:23.75pt; vertical-align:top; width:66.85pt"><p>&nbsp;</p></td><td style="height:23.75pt; vertical-align:top; width:1.0in"><p>Tinnitus</p></td><td style="height:23.75pt; vertical-align:top; width:1.0in"><p>&nbsp;</p></td><td style="height:23.75pt; vertical-align:top; width:63.0pt"><p>&nbsp;</p></td><td style="height:23.75pt; vertical-align:top; width:93.0pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:200.4pt; vertical-align:top; width:87.5pt"><p><strong><em>Cardiac and vascular disorders</em></strong></p></td><td style="height:200.4pt; vertical-align:top; width:53.65pt"><p>Dizziness</p></td><td style="height:200.4pt; vertical-align:top; width:66.85pt"><p>Hypotension, orthostatic hypotension, rhythm disturbances, angina pectoris, tachycardia</p></td><td style="height:200.4pt; vertical-align:top; width:1.0in"><p>Flushing, palpitations, myocardial infarction or cerebro- vascular accident*, possibly secondary to excessive hypotension in high risk patients (see section 4.4)</p></td><td style="height:200.4pt; vertical-align:top; width:1.0in"><p>Raynaud&rsquo;s phenomenon</p></td><td style="height:200.4pt; vertical-align:top; width:63.0pt"><p>&nbsp;</p></td><td style="height:200.4pt; vertical-align:top; width:93.0pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:35.4pt; vertical-align:top; width:87.5pt"><p><strong>System</strong><strong> </strong><strong>organ class</strong></p></td><td style="height:35.4pt; vertical-align:top; width:53.65pt"><p><strong>Very common (&ge;1/10)</strong></p></td><td style="height:35.4pt; vertical-align:top; width:66.85pt"><p><strong>Common</strong><strong> </strong><strong>(&ge;1/100 to</strong></p><p><strong>&lt;1/10)</strong></p></td><td style="height:35.4pt; vertical-align:top; width:1.0in"><p><strong>Uncommon</strong><strong> </strong><strong>(&ge;1/1,000 to</strong></p><p><strong>&lt;1/100)</strong></p></td><td style="height:35.4pt; vertical-align:top; width:1.0in"><p><strong>Rare (&ge;1/10,000 to</strong></p><p><strong>&lt;1/1,000)</strong></p></td><td style="height:35.4pt; vertical-align:top; width:63.0pt"><p><strong>Very rare (&lt;1/10,000)</strong></p></td><td style="height:35.4pt; vertical-align:top; width:93.0pt"><p><strong>Not known (cannot be estimated from the available data)</strong></p></td></tr><tr><td style="border-color:black; height:153.35pt; vertical-align:top; width:87.5pt"><p><strong><em>Respiratory,</em></strong><strong><em> </em></strong><strong><em>thoracic,</em></strong><strong><em> </em></strong><strong><em>and mediastinal disorders</em></strong></p></td><td style="height:153.35pt; vertical-align:top; width:53.65pt"><p>Cough</p></td><td style="height:153.35pt; vertical-align:top; width:66.85pt"><p>Dyspnoea</p></td><td style="height:153.35pt; vertical-align:top; width:1.0in"><p>Rhinorrhoea, sore throat and hoarseness, bronchospasm/ asthma</p></td><td style="height:153.35pt; vertical-align:top; width:1.0in"><p>Pulmonary infiltrates, respiratory distress (including pneumonitis and pulmonary oedema), rhinitis, allergic alveolitis/ eosinophilic pneumonia</p></td><td style="height:153.35pt; vertical-align:top; width:63.0pt"><p>&nbsp;</p></td><td style="height:153.35pt; vertical-align:top; width:93.0pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:129.85pt; vertical-align:top; width:87.5pt"><p><strong><em>Gastrointestinal</em></strong><strong><em> </em></strong><strong><em>disorders</em></strong></p></td><td style="height:129.85pt; vertical-align:top; width:53.65pt"><p>Nausea</p></td><td style="height:129.85pt; vertical-align:top; width:66.85pt"><p>Diarrhoea, abdominal pain</p></td><td style="height:129.85pt; vertical-align:top; width:1.0in"><p>Ileus, pancreatitis, vomiting, dyspepsia, constipation, anorexia, gastric irritations, dry mouth, peptic ulcer, flatulence**</p></td><td style="height:129.85pt; vertical-align:top; width:1.0in"><p>Stomatitis/ aphthous ulcerations, glossitis</p></td><td style="height:129.85pt; vertical-align:top; width:63.0pt"><p>Intestinal angio- oedema</p></td><td style="height:129.85pt; vertical-align:top; width:93.0pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:212.15pt; vertical-align:top; width:87.5pt"><p><strong><em>Hepatobiliary</em></strong><strong><em> </em></strong><strong><em>disorders</em></strong></p></td><td style="height:212.15pt; vertical-align:top; width:53.65pt"><p>&nbsp;</p></td><td style="height:212.15pt; vertical-align:top; width:66.85pt"><p>&nbsp;</p></td><td style="height:212.15pt; vertical-align:top; width:1.0in"><p>&nbsp;</p></td><td style="height:212.15pt; vertical-align:top; width:1.0in"><p>Hepatic failure, hepatic necrosis (may be fatal), hepatitis &ndash; either hepatocellular or cholestatic, jaundice cholecystitis (in particular in patients with pre-existing cholelithiasis)</p></td><td style="height:212.15pt; vertical-align:top; width:63.0pt"><p>&nbsp;</p></td><td style="height:212.15pt; vertical-align:top; width:93.0pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:35.4pt; vertical-align:top; width:87.5pt"><p><strong>System</strong><strong> </strong><strong>organ class</strong></p></td><td style="height:35.4pt; vertical-align:top; width:53.65pt"><p><strong>Very common (&ge;1/10)</strong></p></td><td style="height:35.4pt; vertical-align:top; width:66.85pt"><p><strong>Common</strong><strong> </strong><strong>(&ge;1/100 to</strong></p><p><strong>&lt;1/10)</strong></p></td><td style="height:35.4pt; vertical-align:top; width:1.0in"><p><strong>Uncommon</strong><strong> </strong><strong>(&ge;1/1,000 to</strong></p><p><strong>&lt;1/100)</strong></p></td><td style="height:35.4pt; vertical-align:top; width:1.0in"><p><strong>Rare (&ge;1/10,000 to</strong></p><p><strong>&lt;1/1,000)</strong></p></td><td style="height:35.4pt; vertical-align:top; width:63.0pt"><p><strong>Very rare (&lt;1/10,000)</strong></p></td><td style="height:35.4pt; vertical-align:top; width:93.0pt"><p><strong>Not known (cannot be estimated from the available data)</strong></p></td></tr><tr><td style="border-color:black; height:200.4pt; vertical-align:top; width:87.5pt"><p><strong><em>Skin</em></strong><strong><em> </em></strong><strong><em>and</em></strong><strong><em> </em></strong><strong><em>subcutaneous</em></strong><strong><em> </em></strong><strong><em>tissue</em></strong><strong><em> </em></strong><strong><em>disorders</em></strong></p></td><td style="height:200.4pt; vertical-align:top; width:53.65pt"><p>&nbsp;</p></td><td style="height:200.4pt; vertical-align:top; width:66.85pt"><p>Rash (exanthema) Hyper- sensitivity/ angio- neurotic oedema: angioneurotic oedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported (see section 4.4)</p></td><td style="height:200.4pt; vertical-align:top; width:1.0in"><p>Diaphoresis, pruritus, urticaria, alopecia, photo- sensitivity</p></td><td style="height:200.4pt; vertical-align:top; width:1.0in"><p>Erythema multiforme, Stevens- Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, purpura, cutaneous lupus erythematosus, erythroderma, pemphigus</p></td><td style="height:200.4pt; vertical-align:top; width:63.0pt"><p>&nbsp;</p></td><td style="height:200.4pt; vertical-align:top; width:93.0pt"><p>A symptom complex has been reported which may include some or all of the following: fever, serositis, vasculitis, myalgia/myositis, arthralgia/arthritis, a positive ANA, elevated ESR, eosinophilia, and leucocytosis. Rash, or other dermatologic manifestations may occur.</p></td></tr><tr><td style="border-color:black; height:47.05pt; vertical-align:top; width:87.5pt"><p><strong><em>Musculoskeletal,</em></strong><strong><em> </em></strong><strong><em>connective</em></strong><strong><em> </em></strong><strong><em>tissue,</em></strong><strong><em> </em></strong><strong><em>and bone disorders</em></strong></p></td><td style="height:47.05pt; vertical-align:top; width:53.65pt"><p>&nbsp;</p></td><td style="height:47.05pt; vertical-align:top; width:66.85pt"><p>Muscle cramps***</p></td><td style="height:47.05pt; vertical-align:top; width:1.0in"><p>arthralgia**</p></td><td style="height:47.05pt; vertical-align:top; width:1.0in"><p>&nbsp;</p></td><td style="height:47.05pt; vertical-align:top; width:63.0pt"><p>&nbsp;</p></td><td style="height:47.05pt; vertical-align:top; width:93.0pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:59.3pt; vertical-align:top; width:87.5pt"><p><strong><em>Renal</em></strong><strong><em> </em></strong><strong><em>and urinary disorders</em></strong></p></td><td style="height:59.3pt; vertical-align:top; width:53.65pt"><p>&nbsp;</p></td><td style="height:59.3pt; vertical-align:top; width:66.85pt"><p>&nbsp;</p></td><td style="height:59.3pt; vertical-align:top; width:1.0in"><p>Renal dysfunction, renal failure, proteinuria, glycosuria</p></td><td style="height:59.3pt; vertical-align:top; width:1.0in"><p>Oliguria, interstitial nephritis</p></td><td style="height:59.3pt; vertical-align:top; width:63.0pt"><p>&nbsp;</p></td><td style="height:59.3pt; vertical-align:top; width:93.0pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:35.4pt; vertical-align:top; width:87.5pt"><p><strong><em>Reproductive</em></strong><strong><em> </em></strong><strong><em>system</em></strong><strong><em> </em></strong><strong><em>and breast disorders</em></strong></p></td><td style="height:35.4pt; vertical-align:top; width:53.65pt"><p>&nbsp;</p></td><td style="height:35.4pt; vertical-align:top; width:66.85pt"><p>&nbsp;</p></td><td style="height:35.4pt; vertical-align:top; width:1.0in"><p>Impotence</p></td><td style="height:35.4pt; vertical-align:top; width:1.0in"><p>Gynaecomastia</p></td><td style="height:35.4pt; vertical-align:top; width:63.0pt"><p>&nbsp;</p></td><td style="height:35.4pt; vertical-align:top; width:93.0pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:47.05pt; vertical-align:top; width:87.5pt"><p><strong><em>General</em></strong><strong><em> </em></strong><strong><em>disorders</em></strong><strong><em> </em></strong><strong><em>and administration site conditions</em></strong></p></td><td style="height:47.05pt; vertical-align:top; width:53.65pt"><p>Asthenia</p></td><td style="height:47.05pt; vertical-align:top; width:66.85pt"><p>Chest pain, fatigue</p></td><td style="height:47.05pt; vertical-align:top; width:1.0in"><p>Malaise, fever</p></td><td style="height:47.05pt; vertical-align:top; width:1.0in"><p>&nbsp;</p></td><td style="height:47.05pt; vertical-align:top; width:63.0pt"><p>&nbsp;</p></td><td style="height:47.05pt; vertical-align:top; width:93.0pt"><p>&nbsp;</p></td></tr><tr><td style="border-color:black; height:59.3pt; vertical-align:top; width:87.5pt"><p><strong><em>Investigations</em></strong></p></td><td style="height:59.3pt; vertical-align:top; width:53.65pt"><p>&nbsp;</p></td><td style="height:59.3pt; vertical-align:top; width:66.85pt"><p>Hyper- kalaemia, increases in serum creatinine</p></td><td style="height:59.3pt; vertical-align:top; width:1.0in"><p>Increases in blood urea, hyponatraemia</p></td><td style="height:59.3pt; vertical-align:top; width:1.0in"><p>Elevations of liver enzymes, elevations of serum bilirubin</p></td><td style="height:59.3pt; vertical-align:top; width:63.0pt"><p>&nbsp;</p></td><td style="height:59.3pt; vertical-align:top; width:93.0pt"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>* Incidence rates were comparable to those in the placebo and active control groups in the clinical trials.</p><p>** Only seen with doses of hydrochlorothiazide 12.5 mg and 25 mg</p><p>*** The frequency of muscle cramps as common pertains to doses of hydrochlorothiazide 12.5 mg and 25 mg, whereas, the frequency of the event is uncommon as it pertains to 6 mg doses of hydrochlorothiazide.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via National Pharmacovigilance and Drug Safety Centre (NPC).</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the treatment of overdosage with CO-RENITEC. Treatment is symptomatic and supportive. Therapy with CO-RENITEC should be discontinued and the patient observed closely. Suggested measures include induction of emesis, administration of activated charcoal, administration of a laxative if ingestion is recent, and correction of dehydration, electrolyte imbalance and hypotension by established procedures.</p><p>&nbsp;</p><p><u>Enalapril Maleate</u></p><p>The most prominent features of overdosage reported to date are marked hypotension, beginning some six hours after ingestion of tablets, concomitant with blockade of the renin-angiotensin system, and stupor. Symptoms associated with overdosage of ACE inhibitors may include circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety, and cough. Serum enalaprilat levels 100- and 200-fold higher than usually seen after therapeutic doses have been reported after ingestion of 300 mg and 440 mg of enalapril maleate, respectively.</p><p>&nbsp;</p><p>The recommended treatment of overdosage is intravenous infusion of normal saline solution. If hypotension occurs, the patient should be placed in the shock position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered. If ingestion is recent, take measures aimed at eliminating enalapril maleate (e.g., emesis, gastric lavage, administration of absorbents, and sodium sulphate). Enalaprilat may be removed from the general circulation by haemodialysis (see section 4.4). Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be monitored continuously.</p><p>&nbsp;</p><p><u>Hydrochlorothiazide</u></p><p>The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalaemia, hypochloraemia, hyponatraemia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalaemia may accentuate cardiac arrhythmias.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: enalapril and diuretics, ATC code: C09B A02.</p><p>&nbsp;</p><p>CO-RENITEC (enalapril maleate and hydrochlorothiazide) is a formulation of an angiotensin converting enzyme inhibitor (enalapril maleate) and a diuretic (hydrochlorothiazide) which is effective in the treatment of hypertension. Angiotensin converting enzyme (ACE) is a peptidyl dipeptidase which catalyses the conversion of angiotensin I to the pressor substance angiotensin II. After absorption, enalapril is hydrolysed to enalaprilat, which inhibits ACE. Inhibition of ACE results in decreased plasma angiotensin II, which leads to increased plasma renin activity (due to removal of negative feedback of renin release), and decreased aldosterone secretion. Hydrochlorothiazide is a diuretic and antihypertensive agent which increases plasma renin activity. The mechanism of the antihypertensive effect of thiazides is unknown. Hydrochlorothiazide usually does not affect normal blood pressure.</p><p>&nbsp;</p><p>CO-RENITEC provides antihypertensive and diuretic activities. Enalapril maleate and hydrochlorothiazide have been used singly and concomitantly for the treatment of hypertension. The effect on blood pressure reduction is significantly greater than that seen with enalapril given alone. In addition, the antihypertensive effect of CO-RENITEC was sustained for at least 24 hours.</p><p>&nbsp;</p><p>ACE is identical to kininase II. Thus enalapril may also block the degradation of bradykinin, a potent vasodepressor peptide. However, the role that this plays in the therapeutic effects of enalapril remains to be elucidated.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>While the mechanism through which enalapril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, enalapril is antihypertensive even in patients with low-renin hypertension.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Administration of enalapril to patients with hypertension results in a reduction of both supine and standing blood pressure without a significant increase in heart rate.</p><p>&nbsp;</p><p>Symptomatic postural hypotension is infrequent. In some patients the development of optimal blood pressure reduction may require several weeks of therapy. Abrupt withdrawal of enalapril maleate has not been associated with rapid increase in blood pressure.</p><p>&nbsp;</p><p>Effective inhibition of ACE activity usually occurs 2 to 4 hours after oral administration of an individual dose of enalapril. Onset of antihypertensive activity was usually seen at one hour, with peak reduction of blood pressure achieved by 4 to 6 hours after administration. The duration of effect is dose-related. However, at recommended doses, antihypertensive and hemodynamic effects have been shown to be maintained for at least 24 hours.</p><p>&nbsp;</p><p>In hemodynamic studies with enalapril in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with an increase in cardiac output and little or no change in heart rate. Following administration of enalapril maleate there was an increase in renal blood flow; glomerular filtration rate was unchanged. There was no evidence of sodium or water retention. However, in patients with low pretreatment glomerular filtration rates, the rates were usually increased.</p><p>&nbsp;</p><p>Antihypertensive treatment with enalapril leads to a significant regression of left ventricular hypertrophy with preservation of left ventricular systolic performance.</p><p>&nbsp;</p><p>The effect of the fixed dose combination of enalapril and hydrochlorothiazide on morbidity and mortality has not been studied.</p><p>&nbsp;</p><p><u>Dual Blockade</u></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial), VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>&nbsp;</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>&nbsp;</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Oral enalapril is rapidly absorbed, with peak serum concentrations of enalapril occurring within one hour. Based on urinary recovery, the extent of absorption of enalapril from oral enalapril maleate is approximately 60 %. The absorption of oral enalapril is not influenced by the presence of food in the gastrointestinal tract.</p><p>&nbsp;</p><p>Following absorption, oral enalapril is rapidly and extensively hydrolysed to enalaprilat, a potent angiotensin converting enzyme inhibitor. Peak serum concentrations of enalaprilat occur three to four hours after an oral dose of enalapril. The principal components in urine are enalaprilat, accounting for about 40 % of the dose, and intact enalapril. Except for conversion to enalaprilat, there is no evidence for significant metabolism of enalapril. The serum concentration profile of enalaprilat exhibits a prolonged terminal phase, apparently associated with binding to ACE. In subjects with normal renal function, steady state serum concentrations of enalaprilat were reached after four days of treatment. The extent of absorption and hydrolysis of enalapril are similar for the various doses in the recommended therapeutic range.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Over the range of concentrations which are therapeutically relevant, enalaprilat binding to human plasma proteins does not exceed 60 %.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Except for conversion to enalaprilat, there is no evidence for significant metabolism of enalapril. Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Excretion of enalaprilat is primarily renal. The principal components in urine are enalaprilat, accounting for about 40 % of the dose, and intact enalapril (about 20 %). Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. At least 61 % of the oral dose is eliminated unchanged within 24 hours.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>The exposure of enalapril and enalaprilat is increased in patients with renal insufficiency. In patients with mild to moderate renal insufficiency (creatinine clearance 40-60 ml/min) steady state AUC of enalaprilat was approximately two-fold higher than in patients with normal renal function after administration of 5 mg once daily. In severe renal impairment (creatinine clearance &le; 30 ml/min), AUC was increased approximately 8-fold. The effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at this level of renal insufficiency and time to steady state is delayed (see section 4.2.). Enalaprilat may be removed from the general circulation by haemodialysis. The dialysis clearance is 62 ml/min.</p><p>&nbsp;</p><p><u>Lactation</u></p><p>After a single 20 mg oral dose in five postpartum women, the average peak enalapril milk level was 1.7 &mu;g/L (range 0.54 to 5.9 &mu;g/L) at 4 to 6 hours after the dose. The average</p><p>peak enalaprilat level was 1.7 &mu;g/L (range 1.2 to 2.3 &mu;g/L); peaks occurred at various</p><p>times over the 24-hour period. Using the peak milk level data, the estimated maximum</p><p>intake of an exclusively breast-fed infant would be about 0.16 % of the maternal weight-adjusted dosage. A woman who had been taking oral enalapril 10 mg daily for 11 months</p><p>had peak enalapril milk levels of 2 &mu;g/L 4 hours after a dose and peak enalaprilat levels of 0.75 &mu;g/L about 9 hours after the dose. The total amount of enalapril and enalaprilat measured in milk during the 24 hour period was 1.44 &mu;g/L and 0.63 &mu;g/L of milk respectively. Enalaprilat milk levels were undetectable (&lt;0.2 &mu;g/L) 4 hours after a single dose of enalapril 5 mg in one mother and 10mg in two mothers; enalapril levels were not determined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. Reproductive toxicity studies suggest that enalapril has no effects on fertility and reproductive performance in rats, and is not teratogenic. In a study in which female rats were dosed prior to mating through gestation, an increased incidence of rat pup deaths occurred during lactation. The compound has been shown to cross the placenta and is secreted in milk. Angiotensin converting enzyme inhibitors, as a class, have been shown to be fetotoxic (causing injury and/or death to the fetus) when given in the second or third trimester.</p><p>&nbsp;</p><p>Hydrochlorothiazide crosses the placental but not the blood-brain barrier.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium bicarbonate lactose hydrous corn starch</p><p>yellow ferric oxide (E172) pregelatinised starch magnesium stearate (E572).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium bicarbonate lactose hydrous corn starch</p><p>yellow ferric oxide (E172) pregelatinised starch magnesium stearate (E572).</p><p><strong>&nbsp;</strong></p><p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C. store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Box with three blisters of 10 tablets each and box with two blisters of 14 tablets each. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Merck Sharp & Dohme B.V., Waarderweg 39,
2031 BN Haarlem, P.O. Box 581, 2003 PC Haarlem, 
The Netherlands

Manufacturer:
Merck Sharp & Dohme Ltd. Shotton Lane, 
Cramlington, Northumberland NE23 3JU
UK.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>